Abstract
Paxlovid is a promising, orally bioavailable novel drug for SARS-CoV-2 with excellent safety profiles. Our main goal here is to explore the pharmacometric features of this new antiviral. To provide a detailed assessment of Paxlovid, we propose a hybrid multiscale mathematical approach. We demonstrate that the results of the present in silico evaluation match the clinical expectations remarkably well: on the one hand, our computations successfully replicate the outcome of an actual in vitro experiment; on the other hand, we verify both the sufficiency and the necessity of Paxlovid’s two main components (nirmatrelvir and ritonavir) for a simplified in vivo case. Moreover, in the simulated context of our computational framework, we visualize the importance of early interventions and identify the time window where a unit-length delay causes the highest level of tissue damage. Finally, the results’ sensitivity to the diffusion coefficient of the virus is explored in detail.
Funder
National Research, Development and Innovation Office
Hungarian Academy of Sciences
Subject
Virology,Infectious Diseases
Reference25 articles.
1. PAXLOVID™ (Nirmatrelvir Tablers; Ritonavir Tablets). Pfizer Medical Informationhttps://www.pfizermedicalinformation.com/en-us/nirmatrelvir-tablets-ritonavir-tablets/clinical-pharmacology
2. An oral SARS-CoV-2 M
pro
inhibitor clinical candidate for the treatment of COVID-19
3. Annex I—Conditions of Use, Conditions for Distribution and Patients Targeted and Conditions for Safety Monitoring Addressed to Member States—for Unauthorised Product—Paxlovid (PF-07321332 150 mg and ritonavir 100 mg)—Available for Usehttps://www.ema.europa.eu/en/documents/referral/paxlovid-pf-07321332-ritonavir-covid-19-article-53-procedure-conditions-use-conditions-distribution_en.pdf
4. Mechanistic Modeling of SARS‐CoV‐2 and Other Infectious Diseases and the Effects of Therapeutics
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献